NAMPT inhibitor RPT1G demonstrated favorable safety and significant target engagement in first-in-human study Company to present Trial in Progress design...
– Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant allele burden and...
Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of...
One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable...
Not for distribution by US newswire or in United States TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD....
OSLO, Norway and HOUSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Thor Medical ASA, a leading emerging supplier of alpha-emitters for...
LISLE, IL / ACCESS Newswire / December 3, 2025 / Duly Health and Care, through one of its medical groups,...
DANVILLE, Calif., Dec. 3, 2025 /PRNewswire/ -- Dicom Systems, a leader in enterprise imaging interoperability and workflow orchestration, has reached...
MENLO PARK, Calif. and CINCINNATI, Dec. 3, 2025 /PRNewswire/ -- MyOme, a leading clinical whole-genome testing and polygenic risk modelling...
Highlights The Company has received a Certificate of Grant from the US Patent and Trademark Office for a key patent...
KUALA LUMPUR, Malaysia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) ("BGLC" or the "Company"), a...
Event Scheduled for December 8, 2025 at 12:30 PM ETSAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc....
FDA scientific advice meeting provides guidance on planned Phase 3 study of radiodiagnostic lead candidate in treatment-resistant hypertension / primary...
FREDERICK, Md., Dec. 2, 2025 /PRNewswire/ -- The "Where Energy Meets Matter" exhibition will run through January 20, 2026, at...
Following a $298M Series B, Function is accelerating technology and product leadership to expand AI capabilities and its Medical Intelligence...
FORT MYERS, Fla., Dec. 2, 2025 /PRNewswire/ -- Bridge To A Cure Foundation announces the appointment of Winston Ely to its...
ORLANDO, FLORIDA / ACCESS Newswire / December 2, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on...
US Med-Equip Elves Helping Non-Profit Supporting Hospitalized Children with Cancer HOUSTON, TX / ACCESS Newswire / December 2, 2025 /...
Recognized leader in pathology joins mission to begin clinically offering eLIVE™ to oncologists and pathologistsMADISON, Wis., Dec. 2, 2025 /PRNewswire/...
Eight oral presentations and six posters demonstrate advances in mammography, DBT performance, and density-informed risk modelingSEOUL, South Korea, Dec. 2,...